NCT04377659: An ongoing trial by Memorial Sloan Kettering Cancer Center
This trial is ongoing. It must report results 3 weeks, 6 days from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04377659 |
|---|---|
| Title | A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 1, 2020 |
| Completion date | Oct. 28, 2022 |
| Required reporting date | Oct. 28, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 10, 2023 |
| Days late | None |